Tranilast enhances the effect of anticancer agents in osteosarcoma.
In conclusion, tranilast has a cytostatic effect on osteosarcoma cells and enhances the effect of anticancer drugs, especially cisplatin. Enhanced sensitivity to cisplatin was mediated by increased apoptosis through G2/M arrest. Since tranilast has been clinically approved and has few adverse effects, clinical trials of osteosarcoma chemotherapy in combination with tranilast are expected.
PMID: 31059083 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Methotrexate | Osteosarcoma